Trials / Terminated
TerminatedNCT04230122
A Study of LY3478006 in Healthy Participants
A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3478006 in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to learn more about how safe and how well tolerated LY3478006 is when given by injection into a vein or just under the skin to healthy participants. Blood tests will be done to check how much LY3478006 is in the bloodstream and how long the body takes to get rid of it. For each participant, the study will last up to about 16 weeks, including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3478006 - IV | Administered IV |
| DRUG | LY3478006 - SC | Administered SC |
| DRUG | Placebo - IV | Administered IV |
| DRUG | Placebo - SC | Administered SC |
Timeline
- Start date
- 2020-02-17
- Primary completion
- 2020-06-04
- Completion
- 2020-06-04
- First posted
- 2020-01-18
- Last updated
- 2021-12-06
- Results posted
- 2021-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04230122. Inclusion in this directory is not an endorsement.